Erste Asset Management Gmb H Biomarin Pharmaceutical Inc Transaction History

Erste Asset Management Gmb H

$11.9 Trillion
Q2 2025

A detailed history of Erste Asset Management Gmb H transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Erste Asset Management Gmb H holds 48,796 shares of BMRN stock, worth $2.77 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

48,796

Previous 50,688 3.73%

Holding current value

$2.77 Million

Previous $3.52 Billion 23.47%

% of portfolio

0.02%

Previous 0.05%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$54.08 - $68.32 $102,319 - $129,261	-1,892 Reduced 3.73%	48,796 $2.69 Billion
Q1 2025 May 14, 2025	SELL	$61.25 - $72.83 $1.18 Million - $1.4 Million	-19,247 Reduced 27.52%	50,688 $3.52 Billion
Q4 2024 Feb 10, 2025	SELL	$61.93 - $70.49 $38.4 Million - $43.7 Million	-620,000 Reduced 89.86%	69,935 $4.58 Billion
Q3 2024 Nov 14, 2024	BUY	$69.02 - $93.84 $47.6 Million - $64.7 Million	689,935 New	689,935 $48.5 Billion
Q2 2024 Nov 26, 2024	BUY	$74.43 - $92.22 $5.95 Million - $7.38 Million	80,000 Added 13.03%	694,125 $57.3 Billion
Q1 2024 Nov 26, 2024	SELL	$83.81 - $99.0 $1.68 Million - $1.98 Million	-20,000 Reduced 3.15%	614,125 $53.8 Billion
Q4 2023 Nov 26, 2024	BUY	$76.22 - $98.51 $1.98 Million - $2.56 Million	26,000 Added 4.28%	634,125 $61.2 Billion
Q3 2023 Nov 26, 2024	BUY	$85.07 - $94.48 $7.99 Million - $8.87 Million	93,911 Added 18.26%	608,125 $53.9 Billion
Q2 2023 Nov 26, 2024	BUY	$86.68 - $100.3 $30,164 - $34,904	348 Added 0.06%	589,592 $51.3 Billion
Q1 2023 Nov 26, 2024	BUY	$87.74 - $117.27 $6.49 Million - $8.68 Million	74,010 Added 14.36%	589,244 $57.1 Billion
Q4 2022 Nov 26, 2024	BUY	$80.93 - $108.63 $238,257 - $319,806	2,944 Added 0.58%	514,214 $53.1 Billion
Q3 2022 Nov 26, 2024	SELL	$82.16 - $96.94 $14.4 Million - $16.9 Million	-174,701 Reduced 25.32%	515,234 $43.7 Billion
Q2 2022 Nov 26, 2024	BUY	$71.48 - $86.85 $11.4 Million - $13.8 Million	159,430 Added 45.31%	511,270 $42.5 Billion
Q1 2022 Nov 22, 2024	SELL	$74.28 - $92.69 $3.47 Million - $4.32 Million	-46,650 Reduced 7.67%	561,650 $43.4 Billion
Q4 2021 Nov 22, 2024	SELL	$71.72 - $91.47 $5.85 Million - $7.47 Million	-81,635 Reduced 11.83%	608,300 $54.2 Billion
Q3 2021 Nov 22, 2024	BUY	$74.77 - $85.47 $254,218 - $290,598	3,400 Added 0.56%	608,300 $47 Billion
Q1 2021 Nov 22, 2024	BUY	$74.73 - $90.69 $5.33 Million - $6.47 Million	71,360 Added 13.37%	604,900 $45.6 Billion
Q4 2020 Nov 22, 2024	BUY	$72.61 - $90.2 $5.14 Million - $6.39 Million	70,800 Added 15.3%	533,540 $46.3 Billion
Q3 2020 Nov 22, 2024	SELL	$71.87 - $131.03 $16.3 Million - $29.8 Million	-227,195 Reduced 32.93%	462,740 $35.2 Billion
Q2 2020 Nov 22, 2024	BUY	$79.55 - $124.22 $3.95 Million - $6.17 Million	49,640 Added 15.12%	377,840 $46.5 Billion
Q1 2020 Nov 22, 2024	SELL	$71.37 - $96.85 $7.97 Million - $10.8 Million	-111,700 Reduced 25.39%	328,200 $27.5 Billion
Q4 2019 Nov 22, 2024	SELL	$64.27 - $86.37 $16.1 Million - $21.6 Million	-250,035 Reduced 36.24%	439,900 $37.3 Billion
Q3 2019 Nov 22, 2024	BUY	$67.4 - $85.11 $102,448 - $129,367	1,520 Added 0.37%	407,800 $27.6 Billion
Q2 2019 Nov 22, 2024	BUY	$80.35 - $93.9 $4.36 Million - $5.1 Million	54,300 Added 15.43%	406,280 $34.6 Billion
Q1 2019 Nov 22, 2024	SELL	$84.2 - $98.62 $28.5 Million - $33.3 Million	-337,955 Reduced 48.98%	351,980 $31.2 Billion
Q4 2018 Nov 26, 2024	SELL	$80.14 - $106.07 $27.1 Million - $35.9 Million	-338,095 Reduced 49.0%	351,840 $29.4 Billion

Others Institutions Holding BMRN

# of Institutions

675

Shares Held

185M

Call Options Held

1.31M

Put Options Held

1.1M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $10.6B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Erste Asset Management Gmb H with notifications on news.

Account

Erste Asset Management Gmb H Biomarin Pharmaceutical Inc Transaction History